Incidence of Hepatitis C Virus Infection Among Injection Drug Users During an Outbreak of HIV Infection
Overview
Authors
Affiliations
Background: Beginning in 1994, Vancouver experienced an explosive outbreak of HIV infection among injection drug users (IDUs). The objectives of this study were to measure the prevalence and incidence of hepatitis C virus (HCV) infection in this context and to examine factors associated with HCV seroconversion among IDUs.
Methods: IDUs recruited through a study site and street outreach completed interviewer-administered questionnaires covering subjects' characteristics, behaviour, health status and service utilization and underwent serologic testing for HIV and HCV at baseline and semiannually thereafter. A Cox proportional hazards model was used to identify independent correlates of HCV seroconversion.
Results: As of Nov. 30, 1999, 1345 subjects had been recruited into the study cohort. The prevalence of anti-HCV antibodies was 81.6% (95% confidence interval [CI] 79.6% to 83.6%) at enrollment. Sixty-two HCV seroconversions occurred among 155 IDUs who were initially HCV negative and who returned for follow-up, for an overall incidence density rate of 29.1 per 100 person-years (95% CI 22.3 to 37.3). The HCV incidence remained above 16 per 100 person-years over 3 years of observation (December 1996 to November 1999), whereas HIV incidence declined from more than 19 to less than 5 per 100 person-years. Independent correlates of HCV seroconversion included female sex, cocaine use, injecting at least daily and frequent attendance at a needle exchange program.
Interpretation: Because of high transmissibility of HCV among those injecting frequently and using cocaine, the harm reduction initiatives deployed in Vancouver during the study period proved insufficient to eliminate hepatitis C transmission in this population.
Contextualizing Canada's hepatitis C virus epidemic.
Krajden M, Cook D, Janjua N Can Liver J. 2022; 1(4):218-230.
PMID: 35992621 PMC: 9202764. DOI: 10.3138/canlivj.2018-0011.
HCV Genetic Diversity Can Be Used to Infer Infection Recency and Time since Infection.
Carlisle L, Turk T, Metzner K, Mbunkah H, Shah C, Boni J Viruses. 2020; 12(11).
PMID: 33142675 PMC: 7692400. DOI: 10.3390/v12111241.
OKeefe-Markman C, Lea K, McCabe C, Hyshka E, Bubela T BMC Public Health. 2020; 20(1):89.
PMID: 31959155 PMC: 6971980. DOI: 10.1186/s12889-020-8190-2.
Hepatitis C virus infection in Saskatchewan First Nations communities: Challenges and innovations.
Skinner S, Cote G, Khan I Can Commun Dis Rep. 2019; 44(7-8):173-178.
PMID: 31011298 PMC: 6449086. DOI: 10.14745/ccdr.v44i78a04.
Ulloa A, Puskas C, Yip B, Zhang W, Stanley C, Stone S CMAJ Open. 2019; 7(2):E236-E245.
PMID: 30979728 PMC: 6461542. DOI: 10.9778/cmajo.20180136.